Sai Life Sciences Limited — PPTs, 07-08-2026: Investor Presentation

Sai Life Sciences kicked off FY27 with a robust Q1, reporting revenue of ₹554 Cr, up 12% year-on-year. Its Contract Research Organization (CRO) segment drove significant momentum with 24% YoY growth, while the Contract Development and Manufacturing Organization (CDMO) pipeline strengthened with 33 active commercial molecules. Profit After Tax (PAT) jumped 22% to ₹73 Cr, and EBITDA rose 18% to ₹148 Cr.

The company's strategy focuses on becoming a scientifically-led, integrated partner for large pharma, emphasizing end-to-end development programs and disciplined capital allocation. Key initiatives include expanding into new modalities like Peptides and ADCs, establishing a dedicated peptide platform, and adding a Drug Product facility. Sai is also leveraging digital transformation, AI/ML tools, and High-Throughput Experimentation to accelerate R&D.

Recent developments include operationalizing a new 100,000 sq. ft. R&D facility in Hyderabad and commencing production for three new molecules. The company also earned an EcoVadis Platinum Rating for sustainability. Management projects sustained long-term revenue growth of 15-20% and an EBITDA range of 28-30%, supported by over 90% pipeline visibility for FY27.